TIGIT overexpression
|
Melanoma
|
TIGIT overexpression
|
Melanoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
TIGIT overexpression
|
Melanoma
|
TIGIT overexpression
|
Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
TIGIT overexpression
|
Diffuse Large B Cell Lymphoma
|
TIGIT overexpression
|
Diffuse Large B Cell Lymphoma
|
venetoclax + atezolizumab + obinutuzumab Sensitive: C3 – Early Trials
|
venetoclax + atezolizumab + obinutuzumab Sensitive: C3 – Early Trials
|